HRS-2129 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - P1 | N=202 | Completed | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Recruiting ➔ Completed

Trial completion • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

First-in-Human Phase I Trial of HRS-2129, a Selective Nav1.8 Inhibitor: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects. (PubMed, Drug Des Devel Ther) - P1 | "These results support further clinical development for both acute and chronic pain. http://www.chinadrugtrials.org.cn, identifier NCT06619392 and NCT06742840."

Clinical • First-in-human • Journal • P1 data • PK/PD data • Pain • Renal Disease • NAV1